Oral apixaban for the treatment of acute venous thromboembolism.

By G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus, Margot Johnson, Urszula Masiukiewicz, R. Pak, John R. Thompson, G. Raskob and 1 more. New England Journal of Medicine, 2013

2,195 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/e4e727b66ea90dc46d9452f0849f323906e2e08a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Hematology

S. Konstantinides

In Internal Medicine

Citations in the corpus

ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “inhibitor apixaban (10 mg twice daily for 7 days, followed by 5 mg once daily) with conventional therapy (enoxaparin/warfarin) in 5395 patients with acute VTE, 1836 of whom presented with PE (Table 11).(297) The primary efficacy outcome was recurrent symptomatic VTE or death related to VTE.”
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “apixaban, and edoxaban), and secondary prevention of deep venous thrombosis or pulmonary embolism (rivaroxaban and apixaban only) [119–128].”
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “) with conventional therapy (enoxaparin/warfarin) in 5395 patients with acute VTE, 1836 of whom presented with PE (Table 11).(297) The primary efficacy outcome was recurrent symptomatic VTE or death related to VTE.”
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis (2014, background): “48, respectively).(20) There was never a risk estimate exceeding 1.”
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “lactation, and in patients with antiphospholipid antibody syndrome.(260,261,312) 314 III C”
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, result): “This was in contrast to the reduced bleeding seen in the obese patient group in the AMPLIFY study of apixaban in the treatment of VTE.(330) Similarly in ROCKETAF, obese patients (BMI >_35 kg/m(2)) had a reduced stroke risk compared with the remainder of the cohort, and there was no interaction for t”
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2018, neutral): “9 Currently receiving cancer treatment§ 142 (70) 140 (69) Chemotherapy 120 (85) 113 (81) Radiotherapy 10 (7) 6 (4) Targeted therapy 22 (15) 21 (15) Endocrine therapy 15 (11) 15 (11) Primary tumor type Bladder 4 (2) 10 (5) Brain 2 (1) 1 (1) Breast 20 (10) 20 (10) Cancer unknown primary 3 (2) 3 (1) Ch”